Prometheus Biosciences
3050 Science Park Road
San Diego
CA
92121
United States
Tel: (858) 824-0895
About Prometheus Biosciences
The Power of Precision
65 articles about Prometheus Biosciences
-
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
7/18/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced it will host a virtual R&D Day for analysts and investors at 9:00 am ET on Tuesday, July 26, 2022.
-
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
7/18/2022
Prometheus Biosciences, Inc. today announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase 2 study of PRA023 in ulcerative colitis (UC).
-
Addex Therapeutics announced it is canceling its Phase IIb/III study evaluating its drug dipraglurant due to patient recruiting, staffing and pandemic-related issues.
-
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
6/8/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced an enrollment update on the APOLLO-CD and ARTEMIS-UC trials.
-
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
5/26/2022
Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will present at the Jefferies Healthcare Conference on June 8, 2022 at 10:00 AM ET.
-
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
5/12/2022
Prometheus Biosciences, Inc. reported financial results for the quarter ended March 31, 2022 and highlighted recent corporate progress.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
3/30/2022
Prometheus Biosciences, Inc today announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase 2 study of PRA023 in SSc-ILD.
-
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
3/9/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported financial results for the quarter and full-year ended December 31, 2021 and highlighted recent corporate progress.
-
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
3/1/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO along with members of management, will conduct a virtual fireside chat at the Cowen 42nd Annual Healthcare Conference.
-
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
2/7/2022
Prometheus Biosciences, Inc. announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
1/12/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that management will discuss the following updates at the 40th Annual J.P. Morgan Healthcare Conference.
-
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2022
Prometheus Biosciences, Inc. today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST.
-
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone PaymentInvestigational New Drug Application for PR600 expected in 3Q 2022
1/3/2022
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced it has received its final preclinical milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
12/7/2021
Prometheus Biosciences, Inc. today reported positive topline results from its Phase 1 trial of PRA023 in healthy volunteers. It also announced that it is broadening its pipeline by adding a third indication for PRA023, Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), with the initiation of a Phase 2 clinical trial anticipated for the first quarter of 2022.
-
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
11/12/2021
Prometheus Biosciences, Inc. (Nasdaq: RXDX), today reported financial results for the quarter ended September 30, 2021.
-
Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration with Prometheus Biosciences
11/11/2021
Abveris today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets.
-
Prometheus Biosciences to Present at Upcoming Investor Conferences
11/2/2021
Prometheus Biosciences, Inc. today announced that management will be conducting presentations and fireside chats at the following investor conferences in November and December.n